DiaSorin SpA 2018 AR2
The report highlights DiaSorin's strong financial and non-financial performance for the fiscal year 2018. The company expanded its immunodiagnostic and molecular diagnostics offerings, notably launching the latent tuberculosis test in partnership with QIAGEN. DiaSorin continued the rollout of its LIAISON XL analyzers, reaching an installed base of 7,849 units, and prepared for the launch of the LIAISON XS. On the sustainability front, the company implemented its new HR management system, T.R.U.S.T., and continued its commitment to local communities through initiatives like 'Mad for Science' and the 'Pinocchio Project'.
Company: DiaSorin SpA
Sector: Manufacturing
Country: Italy
Year: 2018
Type: AR2
Pages: 282
Back to company
DiaSorin SpA
Annual Financial Report
The report highlights DiaSorin's strong financial and non-financial performance for the fiscal year 2018. The company expanded its immunodiagnostic and molecular diagnostics offerings, notably launching the latent tuberculosis test in partnership with QIAGEN. DiaSorin continued the rollout of its LIAISON XL analyzers, reaching an installed base of 7,849 units, and prepared for the launch of the LIAISON XS. On the sustainability front, the company implemented its new HR management system, T.R.U.S.T., and continued its commitment to local communities through initiatives like 'Mad for Science' and the 'Pinocchio Project'.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2018
Reporting Period
Jan 1, 2018 - Dec 31, 2018
Fiscal Year
2018
Published
Dec 31, 2018
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Workplace Fatalities
Employees